James M. Scheiman, MD
Professor of Medicine
Division of Gastroenterology
University of Michigan, School of Medicine
Ann Arbor, MI
Darrell T. Hulisz, RPh, PharmD
Department of Family Medicine
Case Western Reserve University, School of Medicine
THIS ACTIVITY WAS ORIGINALLY PRESENTED AS A LIVE SYMPOSIUM ON OCTOBER 25, 2007. IF YOU EARNED CME/CE CREDIT FOR THE LIVE EVENT, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE RELEASE.
Constipation negatively impacts patients’ health-related quality of life, and causes psychological stress and anxiety. Among those who seek treatment for constipation, particularly in the managed care setting, many are not effectively treated and are dissatisfied with treatment outcomes. The etiology of chronic constipation varies tremendously, ranging from metabolic disorders to side effects of common drugs.
The disorder is so common that the American Gastroenterological Association issued official management guidelines in 2000. However, several new pharmacologic agents have been introduced since these guidelines were published. More recently, the AMDA published an algorithm for managing common GI disorders in the long-term care setting.
This program is designed to update healthcare providers and decision makers in the managed care setting in options for developing treatment plans that are successful and cost-effective. The social and economic impact and healthcare costs attributable to constipation are significant, but with education, management of this common condition can be improved.
. Target Audience
This educational activity is designed for managed care pharmacy directors, medical directors, and other pharmacists and physicians who treat patients with chronic constipation.
Upon completion of this educational activity, the participant should be able to:
Summarize the impact of constipation on health-related quality of life.
Describe management strategies for the various etiologies of constipation that are often encountered, including drug-related causes.
Evaluate the clinical impact and cost-effectiveness of traditional and newer treatment options for chronic constipation.
Choose appropriate treatments based on efficacy, safety, and the potential for drug interactions while accounting for co-morbid conditions.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations. AKH planners and reviewers have no relevant financial relationships to disclose.
James M. Scheiman, MD, has served as a consultant for AstraZeneca, Bayer Corporation Pharmaceutical Division, GlaxoSmithKlein, Horizon Therapeutics, Merck and Co., Inc., NiCox, Novartis Pharmaceuticals Corporation, Pfizer Inc, PLx Pharma, Pozen, and TAP Pharmaceutical Products Inc. He has also served as a speaker for AstraZeneca, Santarus, Inc., and Takeda Pharmaceuticals North America, Inc.
Darrell T. Hulisz, RPh, PharmD, has served on speakers bureaus for Pfizer Inc, Novartis Pharmaceuticals Corporation, and Takeda Pharmaceuticals North America, Inc.
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Pharmacists: AKH Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned the Universal Program Number 077-999-08-008-H01-P and is acceptable for 1.25 contact hours (0.125 CEUs).
There is no fee to participate and receive credit. To receive continuing education credit, participants must complete a program evaluation and a post-test with a passing grade of 70% or better. A statement of credit can be printed immediately once the evaluation and post-test are completed. Commercial Support Statements
This activity is supported by an educational grant from Sucampo Pharmaceuticals, Inc. & Takeda Pharmaceuticals North America, Inc.
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next main menu screen will permit you to check for or download the Flash player required to run this program. Clicking on "Click here to start the Virtual Meeting" on this screen will begin the program presentation. The menu at the top of the presentation screen will allow you to view the question and answer segment, the reference list, and the CME/CE post-test and evaluation. The program will take approximately 60 minutes to complete.
Upon completion of the program, click on the post-test button to register and/or access the post-test and program evaluation. Please note that a link to the ASCP website is provided for all pharmacists requesting CPE credit.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CPE/CE certificate/statement.
©2007 Medical Communications Media, Inc. All rights reserved. The opinions expressed in this program are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, Medical Communications Media, AKH Inc., Academy of Managed Care Pharmacy, Sucampo Pharmaceuticals, Inc., or Takeda Pharmaceuticals North America, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.